This morning, the original House sponsors of the Promoting Life-Saving New Therapies for Neonates Act (H.R. 5182), Reps. Billy Long (R-MO) and Ben Ray Luján, published an op-ed in Morning Consult highlighting the need for a new approach to developing medicines for our nation's newborns. The bipartisan duo of lawmakers describe the vital need for new therapies, noting that 1 in 10 babies are born before reaching full-term and that over 90% of the medicines currently given to newborns have not been explicitly tested or endorsed by federal regulators.
"This evidence all points to an urgently needed restructuring of the system we use to promote the development of novel therapies for our newborns," the lawmakers write. "That’s why we are proud to be the House sponsors of the Promoting Life-Saving New Therapies for Neonates Act. In partnership with our Senate colleagues, Sens. Bill Cassidy (R-LA) and Bob Casey (D-PA), we aim to create a new approach in encouraging our medical community to discover breakthrough treatments for healthcare’s most precious patients."
The full op-ed is provided below. To send a letter to your representatives in Congress urging their support for the Promoting Life-Saving Therapies for Neonates act, click here.
"This evidence all points to an urgently needed restructuring of the system we use to promote the development of novel therapies for our newborns," the lawmakers write. "That’s why we are proud to be the House sponsors of the Promoting Life-Saving New Therapies for Neonates Act. In partnership with our Senate colleagues, Sens. Bill Cassidy (R-LA) and Bob Casey (D-PA), we aim to create a new approach in encouraging our medical community to discover breakthrough treatments for healthcare’s most precious patients."
The full op-ed is provided below. To send a letter to your representatives in Congress urging their support for the Promoting Life-Saving Therapies for Neonates act, click here.
